WHAT DO REAL WORLD DATA SAY ABOUT SAFETY AND RESOURCE USE OF ORAL ANTAGONISTS? EARLY ANALYSIS OF NEWLY ANTICOAGULATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS USING EITHER APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN

Published 2016 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
WHAT DO REAL WORLD DATA SAY ABOUT SAFETY AND RESOURCE USE OF ORAL ANTAGONISTS? EARLY ANALYSIS OF NEWLY ANTICOAGULATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS USING EITHER APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 67, Issue 13, Pages 894
Publisher
Elsevier BV
Online
2016-04-01
DOI
10.1016/s0735-1097(16)30895-6

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.